MedTrace Logo

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)

NCT03165045 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1351

Last updated 2020-04-09

Study results available
· View outcomes & findings →

Summary

The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to label after approximately 6 weeks in routine clinical practice.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Spiolto® Respimat®

6 weeks

Sponsors & Collaborators

Principal Investigators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-26
Primary Completion
2019-02-04
Completion
2019-03-24
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03165045 on ClinicalTrials.gov